BriaCell Quadruples Development Free Survival (PFS) in

• Development free survival (PFS) prolonged to 9.1 months in ADC resistant affected person – quadruple the PFS of sufferers in comparable research ^{1, 2, 3}
• Vital discount of “Eye-Bulging” metastatic breast most cancers tumor was beforehand reported
• Closely pre-treated affected person had failed 8 prior regimens together with antibody-drug conjugate (ADC) remedy and continues to obtain BriaCell therapy

PHILADELPHIA and VANCOUVER, British Columbia, July 18, 2024 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Firm”), a clinical-stage biotechnology firm that develops novel immunotherapies to remodel most cancers care, is happy to report considerably increased PFS for its high responder affected person within the Part 2 examine of BriaCell’s Bria-IMT™ routine together with an immune checkpoint inhibitor in metastatic breast most cancers. The affected person stays alive and she or he continues to obtain BriaCell’s therapy routine.

“We’re extraordinarily happy with the unprecedented survival profit on this very-difficult-to-treat affected person,” acknowledged Dr. William V. Williams, BriaCell’s President and CEO. “This information represents a step ahead in our efforts to construct on our data and successes to remodel most cancers look after sufferers. We count on to duplicate this constructive information in our ongoing Part 3 examine and produce reduction to most cancers sufferers whose medical wants stay unmet.”

“Regardless of latest advances in most cancers remedy, metastatic breast most cancers stays an unmet medical want, as present remedies are restricted by poor survival and harsh unintended effects,” commented Dr. Giuseppe Del Priore, BriaCell’s Chief Medical Officer. “The Bria-IMT™ routine produced a for much longer than anticipated survival profit along with its favorable security and tolerability on this affected person suggesting its potential as a therapeutic choice for these most cancers sufferers.”

The affected person had a big proper orbital lesion (behind the appropriate eye) and a proper temporal lobe lesion (in the appropriate facet of the mind). The temporal lobe lesion is not detectable, whereas the orbital lesion has continued to shrink markedly (see determine exhibiting decision of proptosis put up therapy (small arrows) with discount in tumor indicated by the big arrows). As well as, her tumor markers (blood assessments that correlate with the quantity of tumor within the physique) have markedly decreased from her pre-treatment ranges.

Determine 1: Responder Photographs – Bria-IMT™ Routine

^1,2,3 Knowledge is proven for the intent to deal with inhabitants for the management group handled with therapy of doctor’s selection, which is the comparator within the BriaCell’s ongoing pivotal Part 3 examine.
² This paper describes sufferers with mind metastases, which have been additionally current within the affected person described.
⁺ Signifies the affected person is ongoing within the examine.

References

1. Bardia A, et al. Last Outcomes From the Randomized Part III ASCENT Scientific Trial in Metastatic Triple-Unfavourable Breast Most cancers and Affiliation of Outcomes by Human Epidermal Development Issue Receptor 2 and Trophoblast Cell Floor Antigen 2 Expression. J Clin Oncol. 2024 Might 20;42(15):1738-1744. doi: 10.1200/JCO.23.01409. Epub 2024 Feb 29. PMID: 38422473.
2. Tripathy D, et al. Remedy with etirinotecan pegol for sufferers with metastatic breast most cancers and mind metastases: closing outcomes from the section 3 ATTAIN randomized scientific trial. JAMA Oncol. 2022;8(7):1047-1052. doi:10.1001/jamaoncol.2022.0514.
3. O’Shaughnessy J et al. Evaluation of sufferers with out and with an preliminary triple-negative breast most cancers analysis within the section 3 randomized ASCENT examine of sacituzumab govitecan in metastatic triple-negative breast most cancers. Breast Most cancers Res Deal with. 2022 Sep;195(2):127-139. doi: 10.1007/s10549-022-06602-7. Epub 2022 Might 11. PMID: 35545724; PMCID: PMC9374646.

About BriaCell Therapeutics Corp.

BriaCell is a clinical-stage biotechnology firm that develops novel immunotherapies to remodel most cancers care. Extra info is obtainable at https://briacell.com/.

Secure Harbor

This press launch accommodates “forward-looking statements” which can be topic to substantial dangers and uncertainties. All statements, aside from statements of historic truth, contained on this press launch are forward-looking statements. Ahead-looking statements contained on this press launch could also be recognized by way of phrases equivalent to “anticipate,” “imagine,” “ponder,” “might,” “estimate,” “count on,” “intend,” “search,” “might,” “would possibly,” “plan,” “potential,” “predict,” “challenge,” “goal,” “purpose,” “ought to,” “will,” “would,” or the unfavourable of those phrases or different comparable expressions, though not all forward-looking statements include these phrases. Ahead-looking statements, together with these about BriaCell replicating constructive information in its ongoing Part 3 examine; BriaCell’s Bria-IMT™ routine bringing reduction to most cancers sufferers whose medical wants stay unmet; and the Bria-IMT™ routine changing into a therapeutic choice for metastatic breast most cancers sufferers, are primarily based on BriaCell’s present expectations and are topic to inherent uncertainties, dangers, and assumptions which can be tough to foretell. Additional, sure forward-looking statements are primarily based on assumptions as to future occasions that won’t show to be correct. These and different dangers and uncertainties are described extra totally underneath the heading “Dangers and Uncertainties” within the Firm’s most up-to-date Administration’s Dialogue and Evaluation, underneath the heading “Threat Elements” within the Firm’s most up-to-date Annual Data Type, and underneath “Dangers and Uncertainties” within the Firm’s different filings with the Canadian securities regulatory authorities and the U.S. Securities and Change Fee, all of which can be found underneath the Firm’s profiles on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Ahead-looking statements contained on this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no responsibility to replace such info besides as required underneath relevant legislation.

Neither the Toronto Inventory Change nor its Regulation Providers Supplier (as that time period is outlined within the insurance policies of the Toronto Inventory Change) accepts accountability for the adequacy or accuracy of this launch.

Contact Data

Firm Contact:
William V. Williams, MD
President & CEO
1-888-485-6340
information@briacell.com 

Media Relations:
Jules Abraham
CORE IR
julesa@coreir.com

Investor Relations Contact:
CORE IR
traders@briacell.com

A photograph accompanying this announcement is obtainable at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/cef51e5b-ff25-4c3e-929d-22ad6df22927